• Eugene Yuriditsky, Mitchell Oscar J L OJL Division of Pulmonary, Allergy and Critical Care and the Center for Resuscitation Science, Department of Medicine, Hospital of the University of Pe, Shari B Brosnahan, Nathaniel R Smilowitz, Karsten W Drus, Anelly M Gonzales, Yuhe Xia, Sam Parnia, and James M Horowitz.
• Division of Cardiology, Department of Medicine, NYU Langone Medical Center, 550 First Ave, New York, NY 10016, United States.
• Resusc Plus. 2020 Dec 1; 4: 100054.

AimsTo define outcomes of patients with COVID-19 compared to patients without COVID-19 suffering in-hospital cardiac arrest (IHCA).Materials And MethodsWe performed a single-center retrospective study of IHCA cases. Patients with COVID-19 were compared to consecutive patients without COVID-19 from the prior year. Return of spontaneous circulation (ROSC), 30-day survival, and cerebral performance category (CPC) at 30-days were assessed.ResultsFifty-five patients with COVID-19 suffering IHCA were identified and compared to 55 consecutive IHCA patients in 2019. The COVID-19 cohort was more likely to require vasoactive agents (67.3% v 32.7%, p = 0.001), invasive mechanical ventilation (76.4% v 23.6%, p < 0.001), renal replacement therapy (18.2% v 3.6%, p = 0.029) and intensive care unit care (83.6% v 50.9%, p = 0.001) prior to IHCA. Patients with COVID-19 had shorter CPR duration (10 min v 22 min, p = 0.002). ROSC (38.2% v 49.1%, p = 0.336) and 30-day survival (20% v 32.7%, p = 0.194) did not differ. A 30-day cerebral performance category of 1 or 2 was more common among non-COVID patients (27.3% v 9.1%, p = 0.048).ConclusionsReturn of spontaneous circulation and 30-day survival were similar between IHCA patients with and without COVID-19. Compared to previously published data, we report greater ROSC and 30-day survival after IHCA in COVID-19.© 2020 The Author(s).

13 keywords...

hide…